Bristol-Myers Squibb (BMY) AI Stock Analysis

• Market Cap: $94.04B
• Dividend Yield: 5.32%
• Average Volume (3M): 10.34M
• Price to Earnings (P/E): 18.6
• Beta (1Y): 0.25
• Revenue Growth: 2.57%
• EPS Growth: N/A
• Country: US
• Employees: 34,100
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 1.46
• Shares Outstanding: 2,035,435,800
• 10 Day Avg. Volume: 9,561,960
• 30 Day Avg. Volume: 10,344,324
• PEG Ratio: 0.06
• Price to Book (P/B): 7.02
• Price to Sales (P/S): 2.37
• P/FCF Ratio: 8.22
• Enterprise Value/Market Cap: 1.40
• Enterprise Value/Revenue: 2.76
• Enterprise Value/Gross Profit: 4.47
• Enterprise Value/Ebitda: 8.73
• 1Y Price Target: $50.79
• Price Target Upside: 9.94% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 19

• Rating: 68 Neutral
• Price Target: $52.00 ▲(12.55% Upside)

Bristol-Myers Squibb's overall stock score reflects strong financial performance and strategic growth initiatives, as highlighted in the earnings call. The company's robust cash flow and attractive dividend yield further support its valuation. However, high leverage and challenges in legacy portfolios present risks that need to be managed for sustained growth.

Positive Factors

Revenue Growth

Strong revenue growth indicates effective market penetration and product adoption, supporting long-term financial stability and expansion.

Strategic Partnerships

Strategic partnerships enhance R&D capabilities and market reach, fostering innovation and competitive advantage in key therapeutic areas.

Regulatory Progress

Regulatory approvals expand treatment options and market potential, reinforcing the company's leadership in oncology and boosting long-term growth prospects.

Negative Factors

High Leverage

High leverage can strain financial resources, limiting flexibility for investments and increasing vulnerability to economic downturns.

Legacy Portfolio Decline

Decline in legacy products due to generic competition may reduce revenue streams, necessitating successful new product launches to offset losses.

Unmet Expectations in Phase III Trials

Challenges in clinical trials could delay product development and market entry, impacting future growth and innovation pipeline.

Bristol-Myers Squibb Business Overview & Revenue Model

Company Description

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

How the Company Makes Money

Bristol-Myers Squibb generates revenue primarily through the sale of prescription pharmaceutical products. The company's key revenue streams include sales of its oncology drugs, such as Opdivo and Revlimid, alongside its cardiovascular product, Eliquis. These drugs are often prescribed for long-term treatment, resulting in recurring revenue. Additionally, BMY benefits from partnerships and collaborations with other pharmaceutical companies and research institutions, which can provide additional revenue through shared development costs and royalties. The company also engages in licensing agreements that contribute to its earnings. Overall, BMY's diverse product portfolio, combined with strategic collaborations and a focus on high-demand therapeutic areas, underpins its financial performance.

Bristol-Myers Squibb Financial Statement Overview

Summary

Bristol-Myers Squibb demonstrates strong revenue growth and operational efficiency, with a 14.3% increase in revenue and improved gross profit margins. However, high leverage with a debt-to-equity ratio of 2.92 and a relatively low net profit margin of 10.6% indicate areas for improvement. Robust cash flow supports financial stability, but careful debt management is crucial.

Income Statement

Bristol-Myers Squibb shows strong revenue growth in the TTM period with a 14.3% increase, indicating a positive trajectory. The gross profit margin improved to 61.7%, reflecting efficient cost management. However, the net profit margin is relatively low at 10.6%, suggesting room for improvement in profitability. The EBIT and EBITDA margins are healthy, indicating strong operational performance.

Balance Sheet

The company has a high debt-to-equity ratio of 2.92, indicating significant leverage, which could pose risks if not managed carefully. However, the return on equity is strong at 29.6%, showing effective use of equity to generate profits. The equity ratio is not provided, but the overall balance sheet reflects a need for cautious financial management.

Cash Flow

Free cash flow growth is robust at 11.4%, and the operating cash flow to net income ratio is 0.58, indicating good cash generation relative to net income. The free cash flow to net income ratio is high at 0.92, showing strong cash flow relative to earnings. Overall, the cash flow statement reflects solid cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	47.70B	48.30B	45.01B	46.16B	46.38B	42.52B
Gross Profit	29.45B	27.43B	25.36B	26.49B	26.76B	21.70B
EBITDA	15.09B	3.17B	19.37B	19.22B	20.12B	4.93B
Net Income	5.05B	-8.95B	8.03B	6.33B	6.99B	-8.99B
Balance Sheet
Total Assets	94.68B	92.60B	95.16B	96.82B	109.31B	118.48B
Cash, Cash Equivalents and Short-Term Investments	13.60B	10.86B	12.28B	9.25B	17.22B	16.45B
Total Debt	50.93B	51.20B	41.46B	40.72B	45.60B	51.67B
Total Liabilities	77.19B	76.22B	65.67B	65.70B	73.31B	80.60B
Stockholders Equity	17.43B	16.34B	29.43B	31.06B	35.95B	37.82B
Cash Flow
Free Cash Flow	14.58B	13.94B	12.65B	11.95B	15.23B	13.30B
Operating Cash Flow	15.90B	15.19B	13.86B	13.07B	16.21B	14.05B
Investing Cash Flow	-1.39B	-21.35B	-2.29B	-1.06B	-538.00M	-10.86B
Financing Cash Flow	-8.32B	5.13B	-9.42B	-16.96B	-16.22B	-1.15B

Bristol-Myers Squibb Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 46.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMY, the sentiment is Negative. The current price of 46.2 is below the 20-day moving average (MA) of 47.46, below the 50-day MA of 47.07, and below the 200-day MA of 51.58, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 43.25 is Neutral, neither overbought nor oversold. The STOCH value of 41.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BMY.

Bristol-Myers Squibb Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GSK	78 Outperform	$82.06B	18.79	23.04%	4.03%	3.46%	-13.29%
MRK	75 Outperform	$206.84B	12.77	35.44%	3.91%	2.00%	20.01%
PFE	73 Outperform	$135.71B	12.69	12.16%	7.16%	14.72%	―
BMY	68 Neutral	$94.04B	18.64	29.31%	5.32%	2.57%	―
GILD	68 Neutral	$142.13B	22.79	33.26%	2.74%	3.69%	501.26%
AMGN	67 Neutral	$148.80B	22.61	99.14%	3.40%	13.10%	110.67%
Sector *	51 Neutral	$7.93B	-0.35	-43.30%	2.25%	22.54%	-2.22%

Bristol-Myers Squibb Corporate Events

Bristol-Myers Squibb Q2 2025 Financial Results Released

On July 31, 2025, Bristol Myers Squibb reported its financial results for the second quarter of 2025, highlighting a total revenue of $12.3 billion, a 1% increase from the previous year. The company’s Growth Portfolio revenues rose by 18%, driven by strong performances in its immuno-oncology products, while the Legacy Portfolio saw a decline due to generic competition and Medicare Part D impacts. The company raised its 2025 revenue guidance and emphasized its focus on advancing transformational medicines and pipeline opportunities to sustain long-term growth.

The most recent analyst rating on (BMY) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on Bristol-Myers Squibb stock, see the BMY Stock Forecast page.

Bristol-Myers Squibb Appoints New Chief Medical Officer

On July 25, 2025, Bristol Myers Squibb announced the departure of Dr. Samit Hirawat, the Chief Medical Officer and Head of Development, effective November 1, 2025. Dr. Hirawat will transition to an advisory role starting August 1, 2025, and will receive severance benefits and prorated incentives. Concurrently, Dr. Cristian Massacesi will join the company as the new Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025. Dr. Massacesi brings extensive experience from his previous roles at AstraZeneca and Alexion, and his appointment is expected to bolster Bristol Myers Squibb’s efforts in advancing its product pipeline and achieving regulatory approvals.

The most recent analyst rating on (BMY) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on Bristol-Myers Squibb stock, see the BMY Stock Forecast page.